Abstract Search

ea0084op-03-16 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

A clinical and molecular study of a real-world cohort of braf v600e anaplastic thyroid carcinoma treated with dabrafenib and trametinib

Nunes da Silva Tiago , Rodrigues Ricardo , Rito Miguel , Saramago Ana , Pires Carolina , Horta Mariana , Leite Valeriano , Cavaco Branca

Introduction and objectives: Anaplastic thyroid cancer (ATC) has a very low overall survival (OS) and progression free survival (PFS) due to fast growth and resistance to non-target therapies. A recent phase II study showed a dramatic increase in OS and PFS of BRAF V600E mutated ATC patients treated with Dabrafenib and Trametinib (DT). However as commonly reported in melanoma durable responses in ATC may be compromised by resistance mechanisms. Until now only a few ca...

0 shares

ea0084ps3-14-132 | Thyroid Cancer CLINICAL 2 | ETA2022

Efficacy and safety of lenvatinib in a cohort of well-differentiated advanced thyroid carcinomas

Damasio Ines , Maciel Joana , Figueiredo Ana , Simoes Helder , Nunes da Silva Tiago , Simoes-Pereira Joana , Horta Mariana , Santos Rita , Donato Sara , Leite Valeriano

Introduction: Treatment of differentiated thyroid carcinoma (DTC) remains a challenge in the setting of locally advanced or metastatic disease refractory to radiodine (RAI) therapy. SELECT trial demonstrated that Lenvatinib improved progression free survival (PFS) comparing to placebo.Objective: Our aim is to report the efficacy and safety of lenvatinib in our population with aggressive DTC.Methods: We retrospectively reviewed the ...

0 shares

Endocrine Abstracts

A clinical and molecular study of a real-world cohort of braf v600e anaplastic thyroid carcinoma treated with dabrafenib and trametinib

Efficacy and safety of lenvatinib in a cohort of well-differentiated advanced thyroid carcinomas

BiosciAbstracts